Real world evidence (RWE) is evidence that is collected outside of traditional randomized controlled trials (RCTs), such as observational studies and patient registries. While RWE can provide valuable insights into the effectiveness and safety of medical treatments in real-world settings, its robustness can vary depending on a number of factors.

One important factor to consider is the quality of the data sources used to generate RWE. RWE that is based on high-quality, comprehensive data sources such as electronic health records (EHRs) or administrative claims databases may be more robust than RWE that is based on smaller or less comprehensive data sources. Additionally, RWE that is collected using standardized protocols and methods may be more robust than RWE that is collected in an ad hoc or inconsistent manner.

Another important factor to consider is the potential for bias in RWE. Observational studies and other forms of RWE are subject to a number of biases, such as selection bias and confounding, that can affect the accuracy of their findings. While methods such as propensity score matching and sensitivity analyses can help to mitigate these biases, it is important to be aware of their potential impact on the robustness of RWE.

Ultimately, the robustness of RWE will depend on a number of factors, including the quality of the data sources, the methods used to collect and analyze the data, and the potential for bias. While RWE can provide valuable insights into the real-world effectiveness and safety of medical treatments, it should be interpreted with caution and in the context of other available evidence.

Digital health refers to the use of digital technologies, such as mobile devices, wearables, and health apps, to improve healthcare delivery, patient outcomes, and population health. Real-world evidence (RWE), on the other hand, refers to data generated from real-world settings, including electronic health records, claims data, patient-generated data, and data from wearable devices, among others.

In the context of digital health, RWE plays a crucial role in demonstrating the value and effectiveness of digital health interventions. For instance, RWE can be used to evaluate the impact of a mobile health app on patient outcomes, such as improved medication adherence or reduced hospital readmissions. RWE can also be used to identify patient populations that may benefit the most from digital health interventions, as well as to assess the feasibility and scalability of such interventions in real-world settings.

Furthermore, RWE can inform regulatory decision-making around digital health products, such as the approval and reimbursement of digital health interventions. For example, the US Food and Drug Administration (FDA) has established a framework for the use of RWE in regulatory decision-making, which includes the use of RWE to support the approval of digital health products.

Overall, digital health and RWE are closely intertwined, with RWE serving as a key component in the development, evaluation, and implementation of digital health interventions.